**TREX1 Knockdown Induces an Interferon Response to HIV that Delays Viral Infection in Humanized Mice**

**Graphical Abstract**

**Highlights**
- CD4-aptamer-siRNA chimeras knock down TREX1 in CD4+ cells in the genital mucosa.
- Knocking down TREX1 increases type I IFN production by HIV-infected mucosal cells.
- TREX1 knockdown in genital mucosa suppresses HIV infection through IFN induction.
- TREX1 knockdown in the genital tract delays HIV transmission in vivo.

**In Brief**
Wheeler et al. describe the effect of knocking down TREX1 on genital HIV transmission in humanized female mice. Knocking down TREX1 in mucosal CD4+ cells using CD4-aptamer-siRNA chimeras increases type I IFN production by HIV-infected cells and delays HIV infection.

**Authors**
Lee Adam Wheeler, Radiana T. Trifonova, Vladimir Vrbanac, ..., Andrew D. Luster, Andrew M. Tager, Judy Lieberman

**Correspondence**
judy.lieberman@childrens.harvard.edu
**TREX1 Knockdown Induces an Interferon Response to HIV that Delays Viral Infection in Humanized Mice**

Lee Adam Wheeler,1,2,4 Radiana T. Trifonova,1,4 Vladimir Vrbanac,3 Natasha S. Barteneva,1 Xing Liu,1 Brooke Bollman,1 Lauren Onofrey,1 Sachin Mulik,1 Shahin Ranjbar,1 Andrew D. Luster,2 Andrew M. Tager,3 and Judy Lieberman1,*

1Program in Cellular and Molecular Medicine, Boston Children’s Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
2MD-PhD Program, Harvard Medical School, Boston, MA 02115, USA
3Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02139, USA
4Co-first author

*Correspondence: judy.lieberman@childrens.harvard.edu

http://dx.doi.org/10.1016/j.celrep.2016.04.048

**SUMMARY**

Despite their antiviral effect, the in vivo effect of interferons on HIV transmission is difficult to predict, because interferons also activate and recruit HIV-susceptible cells to sites of infection. HIV does not normally induce type I interferons in infected cells, but does if TREX1 is knocked down. Here, we investigated the effect of topical TREX1 knockdown and local interferon production on HIV transmission in human cervicovaginal explants and humanized mice. In explants in which TREX1 was knocked down, HIV induced interferons, which blocked infection. In humanized mice, even though TREX1 knockdown increased infiltrating immune cells, it delayed viral replication for 3–4 weeks. Similarly intravaginal application of type I interferons the day before HIV infection induced interferon responsive genes, reduced inflammation, and decreased viral replication. However, intravenous interferon enhanced inflammation and infection. Thus, in models of human sexual transmission, a localized interferon response inhibits HIV transmission but systemic interferons do not.

**INTRODUCTION**

Most viruses trigger expression of type I interferons (IFNs) when pattern recognition receptors detect viral nucleic acids (Coccia et al., 1994). IFNs orchestrate comprehensive antiviral gene expression programs within infected cells and promote innate and acquired antiviral immune responses by enhancing antigen recognition, lymphocyte activation, and recruitment of immune cells to infection sites. Acute infection with the HIV, however, does not induce antiviral IFNs in the CD4+ T cells and macrophages that are productively infected (Goldfeld et al., 1991; Unterholzner and Bowie, 2008; Yan et al., 2010). HIV evades immune surveillance at multiple stages of the viral life cycle. During viral entry, Toll-like receptor (TLR) RNA sensors do not recognize HIV genomic RNA, because most virions bypass endosomes where these sensors are located. After fusion, genomic RNA is shielded within the viral capsid from cytosolic RNA receptors. HIV reverse transcripts are bound at both ends to HIV integrase, which is predicted to interfere with recognition by cGAS, the cytosolic DNA sensor. However, HIV reverse transcriptase (RT) also generates incomplete reverse transcripts that are not bound to integrase. These can trigger the cGAS-STING-IRF3 pathway of IFN induction if they are not digested by TREX1, a ubiquitous cytosolic 3′–5′ exonuclease (Cai et al., 2014; Gao et al., 2013; Sun et al., 2013; Yan et al., 2009, 2010). When TREX1 is knocked down or knocked out, in vitro HIV infection triggers type I IFN expression in infected cells that inhibits viral replication. Type I IFNs can also be induced by mutating the HIV capsid or depleting host cofactors with which it interacts and by knocking down SAMHD1 (Lahaye et al., 2013; Rasaiyah et al., 2013; Zhang et al., 2014).

Although IFNs have a strong and unequivocal antiviral effect for most viruses, because HIV infects immune cells, the net effect of IFNs on HIV is more complicated. Type I IFNs block both early and late stages of the HIV life cycle (Agy et al., 1995; Coccia et al., 1994; Shirazi and Pitha, 1992). Although type I IFNs also induce the expression of all known HIV restriction factors, including the APOBECs, SAMHD1, and tetherin, type I IFNs can potentially enhance HIV infection by promoting T cell activation and recruiting HIV-susceptible cells to the site of infection. Therefore, although in vitro experiments show that TREX1 deficiency inhibits HIV replication, the in vivo consequences of TREX1 knockdown are difficult to predict.

The antiviral effects of type I IFNs prompted researchers to evaluate their administration as a treatment of HIV infection in the early days of the HIV epidemic. Early studies showed clinical improvement (Hübner et al., 2007; Judge et al., 2005). These promising results were replicated by two randomized control studies, which demonstrated that IFNα treatment significantly reduced viral loads in chronically infected patients (Jackson et al., 2006; Saba et al., 2010). However, subsequent clinical trials did not demonstrate similar therapeutic benefit (Fitzgerald-Bocarsly and Jacobs, 2010; Lehmann et al., 2010; Swiecki and Colonna, 2010). Researchers abandoned IFN-based therapies
when highly active antiretroviral therapy (HAART) became widely available in the mid-1990s (Saba et al., 2010; Wu and KewalRamani, 2006). IFNs, like other cytokines, are meant to act locally at the site of infection and are probably most effective at controlling viral infection when they are produced at high concentrations where the infection begins. The high concentrations required for therapeutic benefit when exogenous IFN is administered lead to systemic side effects, including fever, neutropenia, and depression. The equivocal outcomes of systemic IFN treatment may have been due, in part, to the nonspecific generalized immune activation that accompanies sustained systemic IFN administration. Knocking down TREX1 does not induce IFNs in uninfected cells (Yan et al., 2010), providing a means to localize IFN production to infected cells and evaluate whether IFNs produced in infected cells provide a net protective effect.

Here, we knock down TREX1 using CD4-aptamer-small interfering RNA (siRNA) chimeras (CD4-AsiCs) in CD4+ cells in human cervicovaginal explants and in the genital tract of female humanized mice to evaluate the effect on HIV transmission of localized IFN production in infected cells. We previously showed that CD4-AsiCs, which are composed of a CD4-targeting aptamer covalently linked to the passenger strand of an siRNA and then annealed to the active strand, cause specific gene knockdown in CD4+ T cells and monocytes/macrophages without toxicity, cell activation, or innate immune off-target effects (Wheeler et al., 2011, 2013). Gene knockdown in tissue lasts for almost 2 weeks (Collins et al., 2000; Wheeler et al., 2011). Topical application of CD4-AsiCs designed to knock down CCR5 and/or HIV gag and vif block vaginal transmission in humanized mice.

Because studying early events in the sexual transmission of HIV in humans is difficult, our understanding of sexual transmission of the virus relies heavily on studies in macaques challenged with cell-free simian immunodeficiency virus (SIV) (Arfi et al., 2008; Bergamaschi and Pancino, 2010; d’Ettorre et al., 2014; Miller et al., 2005; Piguet and Steinman, 2007). In this model, SIV first infects and expands in CD4+ T cells in the genital mucosa before spreading to myeloid cells (Haase, 2010; Miller et al., 2005; Zhang et al., 1999). Infection is contained within the genital tract for ~1 week before disseminating to regional lymph nodes and systemically. This provides a “window of opportunity” for interventions to prevent HIV from establishing a foothold. Genital infection stimulates a pro-inflammatory cytokine cascade, which recruits activated immune cells to the genital mucosa (Caux et al., 2000; Dieu-Nosjean et al., 1999; Miller et al., 2005), which then promotes viral replication and spreading, both locally and systemically. Plasmacytoid dendritic cells (pDCs), the primary producers of type I IFNs, are recruited to the genital mucosa, but IFN production is delayed (Klatt et al., 2014). Thus, because SIV does not induce IFNs in infected cells and IFN production by recruited cells in the genital tract is delayed, SIV does not have to cope with the antiviral effects of host IFNs while it is establishing the infection.

A recent study investigated the effect of manipulating type I IFNs on transmission of repeated SIV rectal challenges in rhesus macaques (Sandler et al., 2014). Blocking the type I IFN receptor increased viral replication and AIDS progression, while administration of IFN-α2a around the time of challenge blocked transmission. However, continued exposure to exogenous IFNs actually caused desensitization to its antiviral effect, increased the viral setpoint, and accelerated disease progression. This work highlights the potential protective role of type I IFNs but also suggests that the in vivo effects of IFNs are complex.

Immune responses can differ between human and nonhuman primates, since immune genes continue to coevolve with pathogens, and SIV differs in important ways from HIV. In particular, the SIV viral protein Vpx promotes degradation of host restriction factor SAMHD1, which limits HIV infection in resting T cells and myeloid cells, thereby enabling SIV to replicate in cell populations that HIV cannot. Given the complexity of the effects of IFNs, which activate components of the immune system capable of both propagating and inhibiting HIV (Boasso et al., 2008; Fitzgerald-Bocarsly and Jacobs, 2010; Hardy et al., 2009; Poli et al., 1994), it is important to study the role of IFNs in HIV transmission in human systems. In particular, the exact role IFNs play in acute HIV infection, the timing of their induction, and the effects they exert on their most immediate downstream targets during the earliest stages of viral transmission remain poorly understood. Here, we use two HIV-human transmission model systems, polarized human cervicovaginal explants and humanized mice, to investigate the effect of inducing type I IFNs in infected cells by TREX1 knockdown to assess the effects of endogenous IFNs on HIV female genital transmission. These models both have limitations. The explants are only viable for 10–14 days (Collins et al., 2000; Wheeler et al., 2011) and do not take into account recruitment of immune cells to the tissue. Although human myeloid and lymphoid cells are present in the female genital tract of humanized mice, they are less abundant than in human tissues, and their lymph nodes are often undeveloped or absent (Olesen et al., 2011). Moreover, humanized mice have chronic immune activation from graft versus host responses. Although there is good cross-reactivity between human and mouse cytokines and chemokines, signaling may not replicate precisely what occurs in humans. Nonetheless, these imperfect models are as close as we can get to human transmission.

Here, we show that CD4-AsiCs knock down TREX1 expression by 75%–95% in human cervicovaginal tissue and the female genital tract of humanized mice. Knocking down TREX1 increased expression of type I IFNs and interferon-stimulated genes (ISGs) in HIV-exposed, but not uninfected, human tissue and humanized mice in the first 12–24 hr after exposure, but did not cause upregulation of inflammatory cytokines, such as IL1β, IL-6, and IL-8. Intravaginal (IVAG) IFN administration had a similar effect. In contrast, exogenous IFNs, given intravenously (i.v.) to humanized mice, induced ISGs as well as proinflammatory cytokine gene expression, even in the absence of HIV infection. In tissue explants, TREX1 knockdown suppressed HIV infection, and suppression was largely mediated by type I IFNs, since it was strongly inhibited by neutralizing antibodies to type I IFNs. In humanized mice, a robust type I IFN response decreased viral replication during the first 48 hr after exposure, despite recruitment of immune cells to the genital mucosa. Importantly, TREX1 knockdown in the genital tract delayed HIV infection for ~3–4 weeks, suggesting that IFN induction in infected cells suppresses local viral replication.
RESULTS

TREX1 Knockdown in CD4+ Cells In Vitro and in Human Cervicovaginal Tissue Explants

CD4-AsiCs were designed to knock down TREX1 in CD4+ cells using the CD4 aptamer and siRNA linkage, previously shown to knock down CCR5 and viral genes selectively in CD4+ T cells and macrophages in cervicovaginal tissue explants and the genital tract of humanized mice (Wheeler et al., 2011, 2013). The aptamer directs the chimeric RNA selectively into CD4+ cells, where Dicer cleaves the antisense RNA to generate mature siRNA. A chimeric RNA encoding the CD4 aptamer linked to its 3’-end to the sense strand of one of two TREX1 siRNAs was in vitro transcribed using 2’-fluoropyrimidines to enhance stability and minimize off-target effects (Figures 1A and 1B). The in vitro transcribed RNA was then annealed to the antisense siRNA strand. To evaluate gene knockdown, peripheral blood mononuclear cells (PBMCs) were incubated for 48 hr with 0.25–4 μM TREX1 CD4-AsiCs and analyzed by qRT-PCR for TREX1 mRNA (Figures 1C and 1D). TREX1 knockdown occurred specifically in CD4+, but not CD8+ T cells. The best knockdown occurred using 4 μM AsiC. “Sequence a,” which knocked down TREX1 by ~50% even at the lowest concentration and by ~90% at the highest concentration, was more effective than “sequence b” and was used for subsequent experiments, unless otherwise noted. TREX1 knockdown in primary human CD4+ T cells also significantly reduced TREX1 protein and the proportion of cells that stained above background for TREX1 from 83% to 7%, as assessed by flow cytometry (Figure S1).

Type I IFN signaling leads to phosphorylation and nuclear translocation of the IRF3 transcription factor. To investigate whether IFN signaling is activated after HIV infection in cells knocked down for TREX1, we assessed IRF3 localization by imaging flow cytometry in primary monocyte-derived macrophages (MDMs) and CD4+ T cells (Figures S2A and S2E). TREX1 knockdown did not significantly change IRF3 localization in uninfected cells. However, as expected, IRF3 translocated to the nucleus after HIV infection in cells knocked down with TREX1 siRNA compared to cells transfected with a non-targeting negative control siRNA (MDMs, p < 0.01; CD4+ T cells, p < 0.0001). To determine whether IRF3 activation is mediated by cGAS and IFI16, DNA sensors that recognize HIV reverse transcripts (Gao et al., 2013; Monroe et al., 2014), we co-transfected CD4+ T cells with TREX1 siRNA alone or together with cGAS or IFI16 siRNAs. siRNA targeting the DNA sensor AIM2 or the RNA sensor RIG-I, which are not required for the induction of type I IFN by HIV in TREX1 knockout cells (Yan et al., 2010), were used as controls. Knockdown of cGAS or IFI16, but not AIM2 or DDX58, the gene encoding RIG-I, significantly and strongly inhibited IRF3 nuclear translocation in response to HIV infection in TREX1 knocked down cells (Figures S2F–S2K). Thus, TREX1 knockdown induces IRF3 pathway activation and IRF3 nuclear translocation in response to HIV that is dependent on DNA sensing by both cGAS and IFI16, like recognition of HSV-1 and Listeria monocytogenes DNA (Orzalli et al., 2015; Hansen et al., 2014).

Next, we evaluated TREX1 gene knockdown in human cervicovaginal explants. TREX1 CD4-AsiCs (1 and 4 μM) were applied twice at an interval of 24 hr to the epithelial surface of polarized human cervicovaginal tissue. Four days after the second treatment, tissues were digested to single cell suspensions, which were sorted into CD4+/CD3+ T cells, CD4+/CD14+ macrophages, and CD19+ B cell subsets and analyzed for TREX1 mRNA by qRT-PCR (Figures 1E and 1F). TREX1 was knocked down by 80%–95% in CD4+ T cells and macrophages, but not in B cells. Both concentrations led to comparable knockdown. We previously showed that CD4-AsiCs targeting other genes do not activate an innate immune IFN response on their own (Wheeler et al., 2011). However, because IFN induction may be sequence-dependent, we evaluated whether TREX1-specific CD4-AsiCs induce type I IFNs. We treated cervical explants with TREX1 CD4-AsiCs in the absence of HIV infection and measured expression levels of type I IFN mRNAs in the tissue at the expected peak response time (6 hr) by sensitive qRT-PCR assay (Figure S3A). As expected, TREX1 CD4-AsiCs did not induce an IFN response, whereas Poly(I:C), used as a positive control, did.

TREX1 Knockdown Inhibits HIV Replication and Induces IFN-β in Polarized Human Cervicovaginal Explants

TREX1 knockdown inhibits HIV expression in vitro by upregulating type I IFNs (Yan et al., 2010). To evaluate whether knocking down TREX1 also inhibits HIV infection in human tissue, we used a previously validated polarized human cervicovaginal explant model of HIV transmission and infection. The observed p24 Ag production in infected explants measured active viral replication in the explants, rather than carryover of virus in the infectious inoculum, since p24 Ag levels did not increase in tissues that were infected in the presence of the HIV inhibitors, AZT, or nevirapine (Figure S3B). To evaluate the effect of TREX1 knockdown in the explant system, we measured viral replication in cervicovaginal tissue from three healthy donors infected after they were treated with PBS or CD4-AsiCs against TREX1 or, as positive control, a cocktail against CCR5, gag, and vif. Explants were treated 3 and 2 days prior to challenge with HIV-Bal, and viral replication was monitored by measuring viral p24 antigen in the lower Transwell chamber (Figures S2A–S2C). As previously demonstrated, the CCR5 and antiviral gene cocktail completely prevented productive HIV infection. CD4-AsiCs encoding either TREX1 siRNA sequence inhibited HIV infection, but “sequence a” performed better, almost completely suppressing p24 Ag production. Although HIV infection in the absence of gene knockdown did not lead to detectable IFNβ release until day 9 of culture, when it was barely above background, the infected tissues that were treated with TREX1 AsiCs were infected with IFNβ that was detected in the first measurement on day 3 (Figure 2D). Tissues treated with the more effective “sequence a” AsiC generated more IFNβ. Tissues treated with the CD4-AsiC cocktail that blocked infection did not release IFNβ. To evaluate the importance of type I IFNs in inhibiting HIV transmission in the tissue, blocking monoclonal antibodies (mAbs) to IFNα2 and IFNγ were added to the culture medium 24 hr before and at the time of infection (Figures 2E–2G). The blocking antibodies had no effect on HIV production in explants that were knocked down for CCR5 and the viral genes, which was not surprising since they did not generate type I IFNs. Antibody treatment blunted the amount of...
IFNβ protein detected in the culture supernatants and increased HIV infection in TREX1 AsIC-treated explants. However, blocking IFNα and IFNβ in TREX1 AsIC-treated tissues did not completely restore HIV infection to the level observed in tissues not subjected to knockdown. Thus, TREX1 knockdown suppressed HIV infection in cervicovaginal tissues, largely via induction of type I IFNs.

Recently transmitted HIV-1 viruses, termed transmitted/founder (T/F) viruses, are relatively resistant to suppression by type I IFNs (Parrish et al., 2013). To determine whether TREX1 knockdown could inhibit infection with T/F HIV-1 virus, we compared the effect of TREX1 knockdown on replication of a T/F virus relative to HIVBaL in human cervical explants (Figure S4), using treatment with the CD4 aptamer on its own as a control. T/F virus replication was significantly inhibited by treatment with TREX1 CD4-AsICs. However, T/F virus was less strongly suppressed than HIVBaL.

Exposure of MDMs to Type I IFN Inhibits HIV Replication when Administered Just before or after Infection

To prepare for in vivo experiments with IFNs, we first defined the dose-dependence and timing of IFN protection from HIV infection in vitro. MDMs were incubated for 24 hr with different amounts of a recombinant form of IFN, engineered to bind multiple IFN receptors with high affinity (rIFN), prior to infection with three doses of HIVBaL (Figure S5). Adding 10,000 IU recombinant interferon (rIFN) in 0.3 ml culture medium suppressed viral replication in MDMs by >95% for even the highest viral challenge. At the
Figure 2. CD4-AsiC Knockdown of TREX1 Inhibits HIV Replication in Polarized Human Cervicovaginal Explants Partly by Inducing Type I IFNs

(A–D) Polarized explants (n = 8) from three donors treated with PBS (blue) or twice pretreated with 4 μM CD4-AsiCs targeting TREX1 (siRNA sequence a, light green; siRNA sequence b, dark green) or CCR5, gag, and vif (cocktail, red) before HIV-1 BaL challenge. Data for uninfected control cultures are shown in yellow. Experimental schematic in (A). HIV infection analyzed by p24 Ag ELISA (B and C) and IFN-β protein measured by ELISA (D).

(E–G) Blocking monoclonal antibodies (mAbs) against IFN-α and IFN-β were applied 24 hr prior to and at the time of HIV challenge. Graphs show mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.0005, by Student’s t test, relative to uninfected control. Experimental schematic in (E). Shown is a time course of p24 Ag (F) and IFN-β (G) protein levels in the lower chamber after HIV infection.

See also Figures S2, S3, and S4.
highest concentration, rIFN completely prevented viral replication when added up to 24 hr prior to or within 6 hr after viral challenge. At the lower doses, adding the recombinant protein 6 hr before infection was more effective than adding it 24 hr before infection. When rIFN was added 2 days before or 1 day after viral challenge, there was little protection.

**TREX1 Knockdown IVAG or Topical rIFN Upreregulate ISGs and Inhibit Early HIV Replication in Humanized BLT Mice**

To investigate the in vivo effect of TREX1 expression on HIV transmission, we treated humanized BLT mice IVAG with PBS or 40 pmol of TREX1 CD4-AsiCs on 2 consecutive days. Half of the mice were not exposed to HIV and half were challenged the following day with HIV1_e-RGDS using a viral dose that reproducibly infects all control mice (n = 6) (Wheeler et al., 2011, 2013) (Figure 3A). Additional groups of mice (n = 6) were treated with i.v. rIFN (10^4 IU) or IVAG rIFN (2 x 10^4 IU) the day before viral challenge. One hour post-rIFN administration, we measured rIFN levels in the serum. After i.v. injection, rIFN was detected in the serum at a level of 43.5 ± 0.57 IU/ml (n = 3), but it was not detectable in the serum after IVAG application (data not shown). Mice were sacrificed 16 hr after viral challenge, and cervicovaginal tissue was digested into single cell suspensions. Systemic IFN significantly increased the number of human CD45+ hematopoietic cells in the female genital tract, irrespective of HIV infection, while TREX1 knockdown and topical IVAG IFN increased human infiltrating cells in the genital tract only following HIV infection (Figure 3B). Gene expression was examined in human CD45+ hematopoietic cells, human CD4+ cells, and in the total mixed cell population isolated from the vaginal mucosa by qRT-PCR. TREX1 CD4-AsiCs strongly knocked down TREX1 mRNA (by ~95%) in genital tract CD4+ cells in both HIV-uninfected and infected mice (Figure 3C). Both topical and systemic IFNs significantly increased CCR5 and IFN-responsive TREX1 and APOBEC3G and other ISG mRNAs in tissue CD4+ cells (Figures 3C, 3H, 3I, and 3K). In the absence of HIV infection, TREX1 knockdown did not significantly change expression of inflammatory cytokines, CCR5, type I and II IFNs, or ISGs, including SAMHD1 and APOBEC3G (Figures 3E–3J).

After HIV challenge, HIV gag mRNA was detected above background in control and IFN-treated BLT mouse genital tissue, but was not detected in mice treated with TREX1 AsiCs at this early time point (Figure 3D). Thus, TREX1 knockdown was protective. TREX1 knockdown, and to a greater extent topical and systemic IFNs, also increased CCR5 mRNA in CD4+ cells in the genital tissue, likely due to infiltration of activated immune cells and activation of tissue resident cells (Figures 3B and 3E). With exposure to HIV, TREX1 knockdown led to significantly increased type I and type II IFNs and ISG mRNAs, including the mRNAs for the HIV restriction factor ISGs, SAMHD1 and APOBEC3G (Figures 3H–3J). TREX1 knockdown did not have a consistent effect on HIV-induced inflammatory gene expression—it significantly increased TNFα, reduced IL-1β and IL-8, and did not change IL-6 mRNA expression. Thus, early after HIV infection, TREX1 knockdown in CD4+ cells in the female genital tract reduced HIV load and induced IFNs and antiviral gene expression, but at the same time, increased recruitment of activated CCR5+ immune cells, expanding the numbers of susceptible cells in the tissue.

Topical, but not systemic, IFN significantly suppressed early HIV replication, assessed by measuring gag mRNA 16 hr after infection, compared to control mice, but inhibition was less effective than TREX1 knockdown, which suppressed HIV to undetectable levels (Figure 3D). Systemic rIFN more potently induced ISG expression than TREX1 knockdown, but also enhanced tissue recruitment of CCR5+ hematopoietic cells and caused more pro-inflammatory gene expression. The recruitment of activated HIV-susceptible cells and induction of inflammation in the genital tract after systemic IFN administration may have canceled the antiviral effects of ISGs on HIV replication.

**TREX1 CD4-AsiCs Upregulate Gene Expression of Type I IFNs and ISGs in the Vaginal Tissue of HIV-Exposed Humanized BLT Mice**

Next, we evaluated the effect of TREX1 knockdown on gene expression in the female genital tract of humanized mice 24 and 48 hr after viral challenge (Figure 4A). Mice treated IVAG with TREX1 AsiCs were compared to mice treated IVAG with PBS as negative control, or lipopolysaccharide (LPS), which induces both type I IFNs and inflammatory cytokines, as positive control. Each group was treated on 2 consecutive days and challenged with HIV IVAG on the following day. Blood and cervicovaginal tissue were harvested 24 and 48 hr later, single cell suspensions were prepared, and human CD4+, human CD45+, and total cell populations were analyzed for mRNA expression by qRT-PCR (Figures 4C–4I). IVAG LPS, as expected, increased the numbers of human CD45+ cells in the vaginal tissue (Figure 4B). TREX1 AsiCs knocked down TREX1 in CD4+ cells in the genital tract by...
90% at 24 hr and 75% at 48 hr post challenge, while IVAG LPS significantly increased the expression of IFN-responsive TREX1 in CD4+ cells in vaginal tissue at both time points and in the blood significantly at 48 hr (Figure 4C). HIV infection in genital tract CD4+ cells was suppressed to near background levels by TREX1 knockdown at both time points, while LPS pretreatment enhanced gag mRNA expression in the genital tract. (Figure 4D). Unexpectedly, HIV gag mRNA was detected in blood CD4+ cells of some LPS-treated mice at 48 hr, suggesting that infection may not be restricted to the genital tract in the setting of genital inflammation. However, because gag detection in blood cells was just above background, this finding needs to be interpreted with caution. CCR5 mRNA, an indicator of T cell activation, was significantly decreased in vaginal and blood CD4+ cells in TREX1 AsiC-treated mice, while it was significantly increased in LPS-treated mice in both compartments compared to mock-treated, HIV-infected mice (Figure 4E). Knockdown of TREX1 increased the expression of type I IFNs and ISGs and decreased expression of proinflammatory cytokines in tissue and blood, while LPS pretreatment increased both inflammation and the IFN response (Figure 4F–4I). Thus, TREX1 knockdown in genital CD4+ cells, which enhanced antiviral IFN gene expression and suppressed inflammation, blocked HIV infection at 24 hr and significantly controlled it to near background levels at 48 hr. Generalized innate immune activation by LPS administration in the genital tract enhanced HIV replication locally and accelerated dissemination.

**TREX1 CD4-AsiCs Delay, but Do Not Prevent, Transmission of HIV to Humanized BLT Mice**

To evaluate the net antiviral effect of TREX1 knockdown, we compared HIV infection and CD4+ T cell depletion in humanized mice treated IVAG with TREX1 AsiCs with mock-treated mice and mice treated with the AsiC cocktail against CCR5 and viral genes that blocks viral transmission (Wheeler et al., 2011, 2013) (Figure 5A). (The control group data were previously published in Wheeler et al. [2011], but the TREX1 knockdown data, obtained at the same time, were not previously published.) All mock-treated mice became infected and showed profound CD4+ T cell depletion (Figures 5B–5E). Viremia was first detected 3–4 weeks post-challenge, CD4 counts began to drop within 2 weeks, and CD4+ T cells were severely depleted in all mice by 8 weeks. Mice treated with the cocktail were not infected—they had undetectable viremia, assessed by HIV p24 Ag and HIV gag mRNA, and no change in CD4+ T cell counts. Mice treated with TREX1 AsiCs initially looked like they were protected, but they all developed detectable viremia by 7 weeks. CD4+ T cell depletion only became significant after 9 weeks. Thus, viral production was delayed for ~1 month by knocking down TREX1 prior to viral challenge compared to control mice. Despite the delay in infection, the viral setpoint in TREX1 AsiC-treated mice (~10^5 copies/ml blood) and extent of CD4+ T cell depletion at 12 weeks, when the experiment was terminated, were indistinguishable from those in control mice.

**DISCUSSION**

Here, we demonstrate that TREX1 knockdown using CD4-AsiCs induces expression and secretion of type I IFNs and ISGs in HIV-infected cells that inhibits HIV transmission in human tissue explants and in humanized mice for several weeks when administered prior to viral challenge. Protection from HIV replication in tissue explants was largely abrogated by IFNα/β blocking antibodies, suggesting that protection is mediated by type I IFN production in infected cells. The residual protection may have been due to incomplete blockade of all type I IFNs. We also cannot exclude the possibility that some antiviral effects of TREX1 knockdown are IFN-independent. Indeed, ISGs can be induced in the absence of TREX1 independently of IFNs (Hasan et al., 2013). Within the first 2 days after HIV challenge, HIV replication was not detected in the genital tract of mice treated with TREX1 CD4-AsiCs and was suppressed in mice given rIFN IVAG, suggesting that local IFNs strongly inhibit HIV transmission in vivo. This was despite evidence of significant immune cell infiltration in the genital mucosa and CD4+ T cell activation to express CCR5, the HIV coreceptor used during sexual transmission. In contrast, i.v. administration of rIFN using five times the IVAG dose, which induced local IFN and ISG gene expression in the genital mucosa, but less robustly than IVAG administration, did not inhibit HIV replication at this early time point. Unlike treatment with IVAG IFN or TREX1-AsiCs, i.v. IFN activated proinflammatory cytokine expression (TNFα, IL-1β, IL-6, and IL-8), which likely counteracted the protective effects provided by rIFN.

In some humanized mice (but not those treated with TREX1 CD4-AsiCs), we detected HIV gag RNA at very low levels in CD4+ blood cells as early as 1 and 2 days following IVAG challenge, accompanied by suggestions of systemic immune activation by qRT-PCR analysis of CCR5 and cytokine gene expression in CD4+ blood cells (Figure 4D). Importantly, at these
Figure 5. *TREX1* CD4-AsiCs Delay HIV Transmission to BLT Mice

(A–D) Experimental design indicated in schematic in (A). Mice (n = 4 per treatment group) were treated according to the indicated dosing schedules (right) with PBS (blue, B), a cocktail of CD4-AsiCs targeting CCR5, *gag* and *vif*, using a regimen that previously blocked HIV transmission (red, C) (Wheeler et al., 2011), or *TREX1* CD4-AsiCs (green, D). A total of 40 pmol of each CD4-AsiC was administered IVAG twice according to the dosing schedule. Mice were assessed for HIV (legend continued on next page)
early times, systemic dissemination was exacerbated by IVAG pretreatment with LPS, which caused both local and systemic IFN induction and immune activation. A similar increase in sexual transmission was observed when rhesus macaques treated with IVAG with other TLR agonists were challenged with SIV (Wang et al., 2005). In that case as well, both IFNs and inflammatory cytokines were induced in the genital tract. However, infected cells were not detected in the blood of mice treated IVAG with CD4-AsiCs against TRED1. These data suggest that in humanized mice, HIV may not be contained within the genital tract for the first week after exposure. Nonetheless, we did not detect plasma viremia by RT-PCR or p24 Ag assay until 3 weeks after infection (Figure 5). Because the level of gag mRNA in circulating CD4+ T cells was just above background, the measured gag mRNA in circulating CD4+ T cells within the first few days after infection should be interpreted with caution and needs to be confirmed.

The discrepancy between RT-PCR analysis of CD4+ T cells and plasma viremia assays suggests that RT-PCR analysis of circulating CD4+ T cells may be a more sensitive way to detect systemic dissemination than amplification of viral RNA in circulating virions in the serum. Early dissemination might be the consequence of chronic low levels of immune activation from graft versus host responses that are not completely suppressed in the NOD/SCID/Il2rg-/- (NSG) mice. Their chronic immune activation may mean that conclusions about transmission in humanized mice may not reflect transmission in women, who have no underlying immune activation or vaginal coinfection. However, these mice may be a good model for women with vaginal infections, such as bacterial vaginosis or trichomoniasis infection, who are more vulnerable to becoming infected. If these mouse findings are confirmed, they suggest that it is worth investigating whether early viral dissemination might occur in women with ongoing vaginal or systemic infection.

Although TRED1 knockdown suppressed HIV infection early on, HIV was transmitted with a delay in viral kinetics of 3–4 weeks. In these experiments, TRED1 CD4-AsiCs were administered 1 and 2 days before viral challenge. In an earlier study (Wheeler et al., 2013), CCR5 knockdown in humanized mice using CD4-AsiCs provided complete protection from transmission when HIV challenge occurred within a day of AsiC application, but although gene knockdown in the tissue persisted for 2 weeks, protection was incomplete when HIV challenge was delayed for 4 or 6 days. The lack of complete protection after delayed challenge was attributed to influx of HIV-susceptible cells, not exposed to AsiCs, into the genital mucosa. Similarly, in this study, HIV might have persisted in the tissue (possibly within myeloid cells that do not necessarily replicate the virus, but efficiently transmit it to T cells) (Arfi et al., 2008; Bergamaschi and Pancino, 2010; Kumar et al., 2014; Piguet and Steinman, 2007) and then replicated in tissue resident CD4+ cells in which TRED1 knockdown had waned or in recruited CD4+ T cells that were not present at the time of knockdown. Although the knockdown of TRED1 only delayed the progression of HIV infection, but did not inhibit it completely, the suppression of local HIV replication in the genital tract might reduce person-to-person transmission. Future experiments in which TRED1 AsiCs are administered both before and after HIV challenge should address this question. By measuring viral DNA species and integration of the provirus within different human cell subtypes in the genital tract of humanized mice, we may be able to determine the cell types in which the virus persists during TRED1 knockdown.

The viral setpoint and CD4 depletion in TRED1 knockdown mice eventually reached the same levels as in mock-treated mice. This surprising finding suggests that the viral setpoint is not determined by the original viral replicative burst, but by the complex interaction of the virus with the host immune system. The conservation of the viral setpoint here may be related to the well-known and poorly understood clinical finding that viral levels return to the pretreatment setpoint when antiretroviral drugs are halted. What determines the viral setpoint in any setting is not well understood.

The virodata presented here suggest that there is a narrow temporal window during which IFNs can effectively control infection—the ~30 hr around the time of exposure. Our results echo those found in SIV infection in macaques, in which IFN only effectively blocks infection within a 3-day period (Unterholzer and Bowie, 2008). This may be one of the reasons that chronic IFN therapy showed inconsistent results in clinical trials and ultimately did not appreciably improve patient outcomes (Fitzgerald-Bocarsly and Jacobs, 2010; Jackson et al., 2006; Lehmann et al., 2010; Saba et al., 2010; Swiecki and Colonna, 2010). In addition to timing, location also seems to play a critical role. IFNs at the site of transmission provided protection, but after systemic IFN treatment, protection was lost, likely due to a shift in balance between protective and harmful IFN-triggered downstream events. Our finding in humanized mice differs from results in macaques, where i.v. PEGylated-IFN, begun before SIV challenge and continued for 4 weeks, provided protection from rectal challenge (Unterholzer and Bowie, 2008). Multiple variables could account for these differing observations including differences between species, site of infection, virus, and dose and type of rIFN.

This study uses in vivo gene knockdown as a tool to explore the earliest stages of HIV disease pathogenesis and the role IFNs play in transmission. Knockdown of individual host genes in all the cells that HIV infects using CD4-AsiCs provides a straightforward method to explore the role of individual host genes in HIV transmission. Preliminary results suggest that the CD4-aptamer also recognizes macaque CD4 (data not shown). Thus, this tool could also be used to study the role of host genes in SIV transmission in macaques, where gene knockout is not easy. We have recently found that EpCAM-AsiCs given subcutaneously can silence gene expression in EpCAM+ cells distributed at distal sites throughout the mouse (Gilboa-Geffen et al., 2015). Preliminary studies of subcutaneous injection of CD4-AsiCs in humanized mice also show strong knockdown (~80%) in CD4+ T cells in local lymph nodes, as well as in the...
spleen and distal lymph nodes. These findings suggest that this powerful tool could be used to study the influence of individual host genes not only on transmission, but also on disease progression and pathogenesis.

**EXPERIMENTAL PROCEDURES**

**CD4-AsiCs Synthesis**

CD4-AsiCs were synthesized using the primer sequences given in Table S1 using in vitro transcription as described (Davis et al., 1998; McNamara et al., 2006; Wheeler et al., 2011). Sequences for the conjugated siRNAs are shown in Table S2.

**Human Cervical Polarized Tissue Explants**

Human cervical tissue was obtained with Boston Children's Hospital (BCH) and Harvard Medical School (HMS) Human Investigational Review Board approval from healthy donors undergoing hysterectomy for benign conditions and was prepared as previously described (Wheeler et al., 2011, 2013).

**BLT Mouse Experiments**

Animal work was approved by the Animal Care and Use Committees of Massachusetts General Hospital, BCH and HMS. All in vivo experiments were performed using progesterone-treated, ketamine/xylazine anesthetized NOD/SCID IL2rg<sup>−/−</sup> (NSG) female mice, bearing humanized bone marrow following reconstitution with CD34<sup>+</sup> cells from human fetal liver and surgical human thymic grafts (BLT mice), prepared by the MGH Humanized Mouse Program as previously described (Brainard et al., 2009; Kumar et al., 2008; Wheeler et al., 2011, 2013). Uniform HIV infection in challenge experiments was obtained by requiring high levels of human immune reconstitution using previously described criteria (Wheeler et al., 2011, 2013). These criteria included a minimum of 25% of human CD4<sup>+</sup> cells in the blood, of which at least 50% are lymphocytes (and at least 40% of these are T cells). The absolute number of human T cells was required to be at least 200/100 μl of blood. BLT mice were treated with PBS or 80 pmol of CD4-AsiCs in PBS by atraumatic application to the vaginal mucosa in 15 μl according to the indicated schedule. For infections, HIV<sub>JR-CSF</sub> (10<sup>5</sup> TCID<sub>50</sub>) diluted in 10 μl PBS was applied atraumatically to the vaginal mucosa. Mice were kept supine for 5 min after each application. For some experiments 1 μg/ml of LPS (List Biological Laboratories) was applied IVAG. For other experiments, rIFN (R&D Systems) was administered either by tail vein injection (10,000 IU in 50 μl PBS) or by IVAG administration (2,000 IU in 10 μl PBS). For all post-treatment analysis, both the vaginal tissue and peripheral blood were harvested and processed as previously described (Wheeler et al., 2011, 2013). Single cell suspensions were stained using 1/100 dilutions of hCD45 and hCD4 antibodies (BioLegend) and sorted by FACS for gene expression analysis.

Additional experimental methods are described in the Supplemental Experimental Procedures.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Supplemental Experimental Procedures, five figures, and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2016.04.048.

**AUTHOR CONTRIBUTIONS**

J.L., L.A.W., and R.T. designed the research plan and wrote the manuscript. L.A.W. and R.T. performed experiments with assistance of V.V., N.B., X.L., B.B., L.O., S.M., and S.R. A.D.L. supervised and helped design the humanized mouse experiments.

**ACKNOWLEDGMENTS**

This work was supported by grants from the NIH (AI102816 and AI090671 to J.L.; AI078897 to A.M.T. and A.D.L.), the Harvard CFAR (AI060354 to A.M.T. and A.D.L.), the Ragon Institute (to J.L., A.M.T., and A.D.L.), and fellowships from the Cancer Research Institute, the Adelstein Fund, the Harvard Medical School MD/PhD Program and the Point Foundation (to L.A.W.), and the Harvard CFAR (P30 AI060354 to R.T.). We thank T. Allen and T. Dudek and the Virology Core of the Ragon Institute for providing viral stocks for in vivo studies and E. Oliva, M. Mirti, and A. Bodo, MGH Surgical Pathology, and L. Yang, BidMC, for tissue specimens.

Received: November 3, 2015
Revised: March 21, 2016
Accepted: April 9, 2016
Published: May 12, 2016

**REFERENCES**


Figure S1. Related to Figure 1: Knockdown of TREX1 after treatment with TREX1 CD4-AsiCs. Expression of TREX1 mRNA in human primary CD4+ T cells was measured by qRT-PCR relative to GAPDH (A) and of TREX1 protein was measured by intracellular staining and flow cytometry (B-D) 3 d and 7 d, respectively, after treatment with 2 µM TREX1 AsiC or CD4 aptamer. (**, p< 0.01, ***, p< 0.001). Data are normalized to untreated control and represent mean ± S.E.M.
Figure S2. Related to Figure 2: IRF3 nuclear translocation in HIV-infected cells after TREX1 knockdown.

Nuclear translocation of IRF3 was measured by imaging cytometry performed 16 hrs after HIV infection in primary human MDM (A) and CD4+ T-cells (B) previously transfected with siRNAs targeting TREX1 or with non-targeting negative control siRNA. Shown are representative images of MDMs without (D) or with (E) nuclear IRF3 (BF, brightfield; DAPI, nuclear stain). (F, H, J) Nuclear translocation of IRF3 16 hr after HIV infection of primary human CD4+ T cells transfected with siRNAs targeting TREX1 alone or together with CGAS, IFI16, AIM2 or DDX58, the gene encoding RIG-I. The data were obtained with PBMCs from three healthy donors and at least 5,000 events were analyzed for each condition. Knockdown was confirmed by qRT-PCR 2 d post transfection (C for data in A and B; G, I, K for data in F, H and J, respectively). P values in (C,G,I,K) were calculated by Student's t-test (*, p< 0.001 compared to control). P values in (A,B,F,H,J) were calculated by Chi–squared test (*, p< 0.001, n.s., not significant).
Figure S3. Related to Figure 2: Interferon response after treatment with TREX1 AsiCs and HIV replication in polarized human cervical explants.

(A) Lack of IFN induction in human cervical explants treated with TREX1 AsiC alone. Type I IFN mRNAs were measured by qRT-PCR in polarized cervical explants treated for 6 hrs with 4 µM TREX1 AsiCs. Treatment with 100 µg/ml Poly(I:C) was used as a control (*, p< 0.05, ***, p< 0.001). Data were normalized to GAPDH mRNA. Each bar represents mean ± S.E.M of cervical explants from a single donor. (B) Inhibition of HIV replication in polarized human cervical explants by reverse transcriptase inhibitors. HIV p24 Ag in conditioned media from polarized human cervical explants infected with HIV_{Bal} in the absence or presence of 50 µM Azidothymidine (AZT) or Nevirapine was measured by ELISA. The increasing levels of released p24 that were inhibited by AZT or Nevirapine (***, p<0.001) confirm productive HIV infection in human cervical explants. Data represent mean ± S.E.M.
Figure S4. Related to Figure 2: Inhibition of transmitted/founder (T/F) HIV-1 infection in polarized human cervical explants by TREX1 AsiCs.

HIV p24 Antigen, measured by ELISA, in conditioned media from polarized human cervical explants infected with T/F HIV-1 (pRHPA.c/2635) (A) or HIV_{BaL} (B) after pre-treatment with 2 µM TREX1 AsiC or CD4 aptamer 72 and 48 hr prior to infection (*, p< 0.05, **, p< 0.01). Data represent mean ± S.E.M, normalized to the untreated sample on the same day.
Figure S5. Related to Figure 3 and 4: Treatment with rIFN protects patient-derived MDMs from HIV infection when administered between 24 h prior to infection and 6 h after infection. (A-C) Experimental schema (A) MDMs derived from two healthy donors were pretreated with PBS or rIFN at indicated doses and challenged 24 h later with indicated concentrations of HIV<sub>Bal</sub>. HIV infection was analyzed by p24 Ag ELISA of culture supernatants. (B) shows the time course of infection without IFN pretreatment and (C) shows the relative p24 Ag produced at each timepoint, corrected for background in uninfected samples and normalized to cultures that did not receive rIFN (mock, blue). (D-F) Experimental schema as above, except that rIFN was added to cultures at indicated times before (E) and after (F) HIV challenge. p24 Ag in culture supernatants was normalized to mock cultures that were infected, but did not receive rIFN. All graphs show mean + SEM of 3 independent experiments (*p <0.05, relative to mock-treated sample, by Student’s t-test).
### Table S1: Primers for AsIC Synthesis

<table>
<thead>
<tr>
<th>5’ Primers</th>
<th>CD4 5’ - TAA TAC GAC TCA CTA TAG GGA GAC AAG AAT AAA CGC - 3’</th>
</tr>
</thead>
<tbody>
<tr>
<td>5’ T7 Primer CD4</td>
<td>5’ - GGG AGA CAA GAA TAA ACG CTC AAT GAC GTC CTT AGA ATT GCG CAT TCC TCA CAC AGG ATC TTT TCG ACA GGA GGC TCA CAA CAG GC - 3’</td>
</tr>
</tbody>
</table>

### Template DNA

| CD4 Aptamer | 5’ - GGG AGA CAA GAA TAA ACG CTC AAT GAC GTC CTT AGA ATT GCG CAT TCC TCA CAC AGG ATC TTT TCG ACA GGA GGC TCA CAA CAG GC - 3’ |

### 3’ Primers

<table>
<thead>
<tr>
<th>3’ T7 Primer “Sequence a”</th>
<th>5’ – TCG TAG CGG TCA CCA TTG TGC CTG TTG TGA GCC TCC TGT CGA A - 3’</th>
</tr>
</thead>
<tbody>
<tr>
<td>3’ T7 Primer “Sequence b”</td>
<td>5’ – TGA CAG CAG ATG GTC TTG GGC CTG TTG TGA GCC TCC TGT CGA A - 3’</td>
</tr>
<tr>
<td>3’ CCR5 Primer CD4</td>
<td>5’ - AAT TTC GAC ACC GAA GCA GAG GCC TGT TGT GAG CCT CCT GTC GAA - 3’</td>
</tr>
<tr>
<td>3’ gag Primer CD4</td>
<td>5’ - AAC CTG TCT CTC AGT ACA ATC GCC TGT TGT GAG CCT CCT GTC GAA - 3’</td>
</tr>
<tr>
<td>3’ vif Primer CD4</td>
<td>5’ - AAG GGA TGT GTA CTT CTG AAC GCC TGT TGT GAG CCT CCT GTC GAA - 3’</td>
</tr>
</tbody>
</table>
# Table S2: siRNAs

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sense</th>
<th>Antisense</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCR5</td>
<td>Sense: 5’ P-CUC UGC UUC GGU GUC GAA A dTdT - 3’</td>
<td>Antisense: 5’ P-UUU CGA CAC CGA AGC AGA G dTdT - 3’</td>
</tr>
<tr>
<td>gag</td>
<td>Sense: 5’ P-GAU UGU ACU GAG AGA CAG GCU-dTdT – 3’</td>
<td>Antisense: 5’ P-CCU GUC UCU CUC AGU ACA AUC dTdT-3’</td>
</tr>
<tr>
<td>vif</td>
<td>Sense: 5’ P-GTT CAG AAG TAC ACA TCC C-dTdT</td>
<td>Antisense: 5’ P-GGG AUG UGU ACU UCU GAA CdTdT-3’</td>
</tr>
<tr>
<td>TREX1</td>
<td>Sense: 5’ P- ACA AUG GUG ACC GCU ACG AdTdT -3’</td>
<td>Antisense: 5’ P-TCG TAG CGG TCA CCA TTG TdTdT -3’</td>
</tr>
<tr>
<td>Sequence a</td>
<td>Sense: 5’ P- ACA AUG GUG ACC GCU ACG AdTdT -3’</td>
<td>Antisense: 5’ P-TCG TAG CGG TCA CCA TTG TdTdT -3’</td>
</tr>
</tbody>
</table>
Table S3: Primers for RT-PCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH For</td>
<td>5'- AGC CAC ATC GCT CAG ACA C - 3'</td>
</tr>
<tr>
<td>GAPDH Rev</td>
<td>5'- GCC CAA TAC GAC CAA ATC C - 3'</td>
</tr>
<tr>
<td>IL-8 For</td>
<td>5'- AGA CAG CAG AGC ACA CAA GC - 3'</td>
</tr>
<tr>
<td>IL-8 Rev</td>
<td>5'- ATG GTT CCT TCC GGT GGT - 3'</td>
</tr>
<tr>
<td>IL-6 For</td>
<td>5'- GAT GAG TAC AAA AGT CCT GAT CCA - 3'</td>
</tr>
<tr>
<td>IL-6 Rev</td>
<td>5'- CTG CAG CCA CTG GTG TGT T - 3'</td>
</tr>
<tr>
<td>IFNa For</td>
<td>5' – GCT TTA CTG ATG TCT GTC GTG GTG – 3’</td>
</tr>
<tr>
<td>IFNa Rev</td>
<td>5' – GAG ATT CTG CTC ATT TGT GCC AG - 3’</td>
</tr>
<tr>
<td>IFNβ For</td>
<td>5' – TTG CTC TGG CAC AAC AGG TA - 3’</td>
</tr>
<tr>
<td>IFNβ Rev</td>
<td>5' – TGG AGA AGC AAC CAG GAG A - 3’</td>
</tr>
<tr>
<td>IFNγ For</td>
<td>5' – GGC ATT TTG AAG AAT TGG AAA G - 3’</td>
</tr>
<tr>
<td>IFNγ Rev</td>
<td>5' – TTG GGA TGC TCT GGT CAT CT - 3’</td>
</tr>
<tr>
<td>OAS-1 For</td>
<td>5' – GGT GGA GTT CGA TGT GCT G - 3’</td>
</tr>
<tr>
<td>OAS-1 Rev</td>
<td>5' – AGG TTT ATA GCC GCC AGT CA - 3’</td>
</tr>
<tr>
<td>IP-10 For</td>
<td>5' – GAA AGC AGT TAG CAA GGA AAG GT - 3’</td>
</tr>
<tr>
<td>IP-10 Rev</td>
<td>5' – GAC ATA TAC TCC ATG TAG GGA AGT GA - 3’</td>
</tr>
<tr>
<td>STAT1 For</td>
<td>5' – TTG GCA CCT AAC GTG CTG - 3’</td>
</tr>
<tr>
<td>STAT1 Rev</td>
<td>5' – TTC GTA CCA CTG AGA CAT CCT G - 3’</td>
</tr>
<tr>
<td>IL-12 For</td>
<td>5' – CAC TCC CAA AAC CTG CTG AG - 3’</td>
</tr>
<tr>
<td>IL-12 Rev</td>
<td>5' – TCT CTT CAG AAG TGC AAG GGT A - 3’</td>
</tr>
<tr>
<td>HIV- gag For</td>
<td>5' – AGT GGG GGG ACA TCA AGC AGC CAT GCA AAT – 3’</td>
</tr>
<tr>
<td>HIV- gag Rev</td>
<td>5' – TGC TAT GTC ACT TCC CCT TGG TTC TCT – 3’</td>
</tr>
<tr>
<td>TREX1 For</td>
<td>5' – GCA TCT GTC AGT GGA GAC CA – 3’</td>
</tr>
<tr>
<td>TREX1 Rev</td>
<td>5' – AGA TCC TTG GTA CCC CTG CT – 3’</td>
</tr>
<tr>
<td>IL1-β For</td>
<td>5' – GTG AAA TGA TGG CTT ATT ACA GTG – 3’</td>
</tr>
<tr>
<td>IL1-β Rev</td>
<td>5' – CTG AGC CGG CCT GCC TGA AGC CCT – 3’</td>
</tr>
<tr>
<td>TNFa For/Rev</td>
<td>IDT Prime Time Primer Sequence Hs.PT.58.45380900</td>
</tr>
<tr>
<td>CCR5 For/Rev</td>
<td>IDT Prime Time Primer Sequence Hs.PT.58.3437570</td>
</tr>
<tr>
<td>cGAS For</td>
<td>5' – GGG AGC CCT GCT GTA ACA CTT CTT AT – 3’</td>
</tr>
<tr>
<td>cGAS Rev</td>
<td>5' – CCT TTG CAT GCT TGG GTA CAA GGT – 3’</td>
</tr>
<tr>
<td>IFI16 For</td>
<td>5' – GGT CTG CGA TCC TGA ATG GG – 3’</td>
</tr>
<tr>
<td>IFI16 Rev</td>
<td>5' – TCA CTA TCG AGA TAC TTG TGG GT – 3’</td>
</tr>
<tr>
<td>AIM2 For</td>
<td>5' – TGG CAA AAC GTC TTC AGG AGG – 3’</td>
</tr>
<tr>
<td>AIM2 Rev</td>
<td>5' – AGC TTG ACT TAG TGG CTT TGG – 3’</td>
</tr>
<tr>
<td>DDX58 For</td>
<td>5' – GTG CAA AGC CTT GGC ATG T – 3’</td>
</tr>
<tr>
<td>DDX58 Rev</td>
<td>5' – TGG CTT GGG ATG TGG TCT ACT C – 3’</td>
</tr>
</tbody>
</table>
Supplemental Experimental Procedures

Cells. Human PBMCs were isolated by Ficoll (GE) density centrifugation from whole blood obtained from the Kraft Family Blood Donor Center and from the Brigham and Women’s Hospital Specimen Bank, Boston, MA with Institutional Review Board approval. Mononuclear cells were cultured in H10 medium (RPMI 1640 (Cellgro) containing 10% Human AB serum (GemCell), 100 U/mL penicillin and 100 µg/mL streptomycin sulfate). CD4+ cells were separated using immunomagnetic beads (Miltenyi) and CD4+ T cells and MDMs were prepared as previously described (Song et al., 2003). T cells were cultured in H10 containing 60 IU/mL IL-2 (Proleukin from Chiron Corporation, Emeryville, CA) and were activated using 4 µg/mL PHA (Difco). Resting PBMCs were cultured in H10 containing 4 µg/mL IL-15 (R&D Systems).

Quantitative RT-PCR (qRT-PCR) was performed as previously described (Palliser et al., 2006) using primers in Table S3. mRNA expression was normalized to GAPDH expression, and then calculated as a percentage relative to mock-treated controls.

Flow cytometry. Direct immunostaining of CD3, CD4, CD8, CD14, CD45, and CD19 was performed using 1/20 dilutions of fluorescently conjugated murine mAb (BioLegend) for 30-60 min at 4 °C. Cells were stained in PBS containing 0.5% FCS, 1 mM EDTA, and 25 mM HEPES. Samples were washed twice in the same buffer. Intracellular flow cytometry for TREX1 was performed using a rabbit monoclonal antibody (Abcam, Cambridge, MA) with a donkey anti-rabbit AF647 secondary antibody (Life Technologies). Data were acquired for one and two-color experiments using a FACScalibur (BD Biosciences), and for multi-color and cell sorting experiments using a FACSaria II (BD Biosciences). All data were analyzed using FlowJo (Treestar, Inc.) software.

Viruses. HIV$_{\text{fad}}$ was used to infect cells and cervicovaginal explants in vitro unless otherwise specified. HIV$_{\text{fad}}$ was used to infect primary CD4+ T cells. HIV$_{\text{fad}}$ and HIV$_{\text{f184}}$ were obtained from the NIH AIDS Research and Reference Reagent Program and viral stocks were generated as previously described (Wheeler et al., 2011; Wheeler et al., 2013). For mouse experiments HIV-1$_{\text{R,CSF}}$ stocks were produced by the Virology Core of the Ragon Institute as previously described (Wheeler et al., 2013). T/F HIV-1 Infectious Molecular Clone (pRHPA.c/2635) was obtained from the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH (cat#11744, from Dr. John Kappes). T/F HIV-1 and HIV$_{\text{fad}}$ (200 µL of 1x10$^5$ TCID50/mL virus) were used to infect polarized human cervical explants.

Human cervical polarized tissue explants. AsiCs or aptamers in 50 µL OptiMem (Invitrogen) were applied on 2 consecutive days to the apical surface of polarized explants, and the explants were then incubated at 37 °C for 4-6 h before adding 150 µL H10 medium to each well. In some experiments 15 µg of neutralizing antibodies against both IFNα and IFNβ (Cell Sciences and BioLegend, respectively) were added to the culture medium at the same time as the second topical AsiC administration and at the time of HIV infection. At sequential time points, 100 µL of medium from the lower chamber was removed for HIV and IFNβ ELISA assays. Explants were cultured for not more than 10 d to reduce confounding problems due to loss of viability during extended culture. Cervicovaginal tissue was digested with collagenase as previously described (Wheeler et al., 2011; Wheeler et al., 2013). Cell subsets were obtained by fluorescence-activated cell sorting after staining for CD4, CD14, CD3 and CD19. RNA from separated monocyte, CD4 T cell and B cell subsets were analyzed by qRT-PCR.

ELISA assays. p24 antigen levels were measured using the HIV-1 p24 ELISA Kit (Perkin Elmer). IFNβ protein was measured by assay of culture supernatants using the Verikine Human IFN beta ELISA kit (R&D). rhIFN Type I was measured in mouse serum samples using Human IFN-alpha Serum Sample ELISA Kit (R & D Systems).

rIFN. A universal Type I IFN (R&D Systems) was used for both in vitro and in vivo experiments.

Analysis of HIV infection. Blood was obtained by venipuncture of the facial vein at weekly intervals for 12 wks following HIV challenge. Analysis of HIV infection was as previously described (Wheeler et al., 2011; Wheeler et al., 2013). Cells were pelleted by centrifugation and plasma was stored at -80 °C until analysis. Cell pellets were twice treated with red blood cell (RBC) lysis buffer (Sigma), washed with flow cytometry buffer described above and stained using a 1/20 dilution of CD3, CD4, and CD8 mAb (BioLegend). Viral RNA was extracted from 75 µL of plasma using Trizol (Invitrogen) according to the manufacturer’s instructions. cDNA was reverse transcribed.
using SuperscriptIII (Invitrogen) and HIV gag mRNA was assessed by qRT-PCR using gag-specific primers (Table S3). The remaining serum was aliquoted for p24 Ag ELISA (Perkin Elmer).

**Imaging cytometry.** MDMs and human primary CD4+ T cells were knocked down for TREX1, cGAS, IFI16, AIM2, DDX58 as indicated, by siRNA nucleofection as previously described (Yan et al., 2010), and infected 3 days later with HIV<sub>B</sub> and HIV<sub>IIIB</sub>, respectively. siRNAs targeting TREX1 were pro-siRNAs produced in bacteria as described (Huang and Lieberman, 2013). siRNAs targeting cGAS, IFI16, AIM2 and DDX58 were from Dharmacon (siGENOME™ SMARTpool, except AIM2 siRNA which were ON-TARGET plus). Non-targeting negative control siRNA was from Ambion (Silencer® Select Negative Control No. 1 siRNA, cat#4390843). Knockdown was confirmed by qRT-PCR 2 d post transfection. Cells were stained 16 hr post infection with DAPI (Sigma) and IRF3 rabbit monoclonal antibody (AbCAM) or rabbit IgG (AbCAM) as control and then donkey anti-rabbit AF647 secondary antibody (Life Technologies) using BD Cytofix/Cytoperm kit (BD Biosciences). Nuclear translocation of IRF3 was assessed using a 5-laser ImageStream X Mark II imaging cytometer (Amnis-Millipore) as described (Fasler-Kan et al, 2016). Cell populations were sequentially gated on single cells positive for DAPI and IRF3 staining. Image analysis was performed using a nuclear mask and Imagestream Data Exploration and Analysis Software (IDEAS) 6.1 (Amnis-Millipore). The similarity score parameter, a log-transformed Pearson correlation coefficient of the pixel values of two images, was used to correlate the location of IRF3 staining and the nuclear dye (DAPI) to identify cells with nuclear IRF3.

**Statistical analysis.** Data for most experiments were analyzed by Student's t-test. All P-values are for two-tailed significance tests. For analysis of data based on independent experiments using samples from multiple donors, one-way analysis of variance (ANOVA) with Dunnet multiple comparison test was performed using GraphPad Prism (GraphPad Software). P values for the imaging cytometry experiment were calculated by Chi-squared test. P values below 0.05 were considered significant. The limit of detection of HIV infection was calculated for each assay using the method of (Armbruster and Pry, 2008).

**Supplemental References**


